$ORGO News

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution

Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary

Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2

Organogenesis Q2 Earnings Call Highlights

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript

Organogenesis Holdings (NASDAQ:ORGO) Plunges 17% as Q2 Revenue and EPS Miss Estimates

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

Organogenesis' Biologics License Application For ReNu Receives FDA's Acceptance For Review To Treat Pain In Symptomatic Knee Osteoarthritis

Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked

Truist Securities Initiates Coverage On Organogenesis Holdings with Hold Rating, Announces Price Target of $3

Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update

Spotlight On Penny Stocks To Consider In May 2026

Undervalued Small Caps With Insider Buying To Watch In May 2026

Organogenesis (ORGO) Q1 2026 Earnings Transcript